Dr. Heidi Overton, nominated by former President Donald Trump to head the Food and Drug Administration (FDA), could bring renewed scrutiny to mifepristone, the abortion drug currently under federal safety review. John Mize, CEO of Americans United for Life (AUL), expressed optimism that Overton, known for her pro-life views, would bring an objective perspective to the drug's risks.
"I think she’s going to bring objectivity to the issue of mifepristone in a way that will expose this drug for the damage it causes women," Mize told Fox News Digital. He added that his organization is hopeful Overton will serve as a "pro-life FDA commissioner."
Overton's nomination follows a case in North Carolina where an 18-year-old woman was accused of using mifepristone and misoprostol to terminate a pregnancy at 31 weeks, significantly beyond the FDA's approved limit of 10 weeks for mifepristone.
Mize, who has led AUL since its founding in 1971, believes Overton is well-suited for the FDA leadership role, citing her background in government, clinical medicine, and medical research. If confirmed, she would oversee the regulation of medications like mifepristone.
Mifepristone carries an FDA boxed warning, the agency's highest safety alert, due to the risk of severe infections or bleeding. The FDA suspended enforcement of the drug's in-person dispensing requirement in 2021 amid COVID-19 restrictions and later removed it permanently after reviewing safety data. Current FDA regulations permit mifepristone to be prescribed via telehealth and mailed by certified pharmacies.
"Dr. Overton and I share a very similar perspective that the drug is dangerous, particularly in an unregulated way for women," Mize stated. "I firmly believe she understands the clinical implications of taking a drug with a black box warning and now shipping it in the mail."
Overton has previously expressed criticism of abortion medications, which accounted for approximately 65% of clinician-provided abortions in 2023, according to the Guttmacher Institute. In a 2023 policy brief for the America First Policy Institute, she criticized federal policymakers for expanding access to abortion pills and accused the Biden administration of misusing the COVID-19 pandemic to justify mailing mifepristone and misoprostol to patients.
"Abortion is corrosive to children, women, and society broadly because it devalues and extinguishes innocent human life," Overton wrote at the time. "America First policies should focus on immediately halting the effort to normalize abortion-on-demand and on broadly recognizing the evidence of the risk posed to women."
Mize referenced a 2025 study by the Ethics and Public Policy Center that analyzed insurance claims for mifepristone abortions between 2017 and 2023. The study reported a nearly 11% rate of serious adverse events, including hemorrhaging, sepsis, or infection. Mize acknowledged that the study faced criticism for its methodology and was not peer-reviewed, but suggested Overton is aware of these limitations.
"It’s not the whole picture, and Dr. Overton would say that," Mize said. "But it’s an important indicator as to what’s happening in the real world. So I believe she will do a really good job of evaluating the study."
Mize hopes Overton will implement stricter regulations on mifepristone, potentially reinstating an in-person doctor visit requirement before prescription. He described Overton as "measured" and "methodical," cautioning that sweeping changes might not occur immediately.
If confirmed, Overton would inherit an ongoing FDA safety review of mifepristone, which began in September 2025 with no set completion date. The FDA typically takes a year or longer for such studies. Mize suggested that a subsequent, in-depth evaluation would be necessary to determine if the drug should remain on the market.
Overton's confirmation hearing has not yet been scheduled but is anticipated after the Senate reconvenes on September 14.